Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer And Cadila Pool Products To Form Equal Stake JV For India Market

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise

You may also be interested in...



Bayer Challenges Nexavar Compulsory License To Natco; Says It Endangers Pharma Research

The German firm says challenges faced by the Indian healthcare system has little or nothing to do with patents

Bayer Expects Big Gains In APAC With Late-stage Pipeline And Zydus Cadila Joint Venture

Bayer expects half of its 43 clinical trials to be ready for the market in the next few years in Southeast Asia.

Bayer Lines Up Investments Worth €1.8 Billion To Expand In Asia

The German conglomerate targets doubling China and India sales by 2015

Related Content

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel